With Maunjaro’s recent launch in India, filmmaker Hansal Mehta opened about using the drug to manage weight and blood sugar.

Known for the work acclaimed by his critics in Indian cinema, Mehta shared an individual account of his health journey, while challenging the stigma around using medical intervention for weight loss.

In his post, Mehta revealed that he is using a newly launched anti-diobler and weight management drugs, silence under pre-diabetes and medical supervision to increase stable weight.

“Under medical guidance, I began silently to address the growing blood sugar levels in the pre-diabetic range and manage my ever increasing weight,” Mehta wrote.

He explained that the drug was part of a broader lifestyle change that included high-protein food, intermittent fasting, strength training, hydration and better sleep.

“Within a few months, I am about 10 kg, my energy levels are higher, and my blood sugar readings are now well within the normal range,” he wrote.

Mehta’s post not only highlights their change, but also explains the stigma around the use of new generation drugs like Maunzaro.

He said, “I am sharing it because these new drugs have unnecessary stigma and those who use them connect their newly found health for unclear and often disappointing fitness,” he wrote, resolving prior perceptions about weight -losing drugs.

He said, “There is no shame in taking charge of your health with the equipment available to you, especially when it is done responsibly and under supervision,” he said, encouraging others to consult doctors if they face similar health challenges, “he said.

Mounjaro (Tirzepatide) developed by the US -based pharmaceutical company Eli Lily was recently launched in India after receiving the Marketing Authority from the Central Drugs Standard Control Organization (CDSCO).

The drug type 2 is approved for diabetes and weight management, and is now available as a single-bottle vial in the country.

Unlike chronic drugs, which mainly target a hormone, works by activating two hormones, GIPs and GLP -1 to control both blood sugar levels and hunger. This dual-action mechanism is one that makes the drug effective for people dealing with obesity or insulin resistance.

It is a prescription drug, which is to be used with a healthy diet and exercise.

It is generally recommended for this:

• 30 or more (obesity) with BMI adults
• Adults with BMIs of 27 or more also have weight related health issues
• Type 2 diabetes adults for better blood sugar management

Since the drug affects hormones and metabolism, the dose and duration of treatment should be carefully determined by a health professional.

The 2.5 mg single-dose vial costs Rs 3,500, while the 5 mg vial is priced at Rs 4,375, which is a fraction of the cost sold in the US. For a specific early dose of 2.5 mg of weekly, the monthly cost is about Rs 14,000.

The launch of Maunjaro in India is being seen as an important step in the treatment of obesity and diabetes related conditions, which is asked to get the drug catch with several inquiries.